Cardiovascular disease after cancer therapy

Berthe M.P. Aleman a,*, Elizabeth C. Moser b, Janine Nuver c, Thomas M. Suter d, Maja V. Maraldo e, Lena Specht e, Conny Vrieling f, Sarah C. Darby g

a Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
b Department of Radiotherapy and Breast Unit, Champalimaud Foundation, Lisbon, Portugal
c Department of Medical Oncology, University Medical Center Groningen, Groningen, The Netherlands
d Department of Cardiology, Bern University Hospital, Bern, Switzerland
e Department of Oncology and Haematology, Rigshospitalet, University of Copenhagen, Denmark
f Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
g Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom

ARTICLE INFO

Article history:
Received 26 March 2014
Accepted 26 March 2014

Keywords:
Cardiovascular
Disease
Therapy
Cancer
Oncology

ABSTRACT

Improvements in treatment and earlier diagnosis have both contributed to increased survival for many cancer patients. Unfortunately, many treatments carry a risk of late effects including cardiovascular diseases (CVDs), possibly leading to significant morbidity and mortality. In this paper we describe current knowledge of the cardiotoxicity arising from cancer treatments, outline gaps in knowledge, and indicate directions for future research and guideline development, as discussed during the 2014 Cancer Survivorship Summit organised by the European Organisation for Research and Treatment of Cancer (EORTC). Better knowledge is needed of the late effects of modern systemic treatments and of radiotherapy to critical structures of the heart, including the effect of both radiation dose and volume of the heart exposed. Research elucidating the extent to which treatments interact in causing CVD, and the mechanisms involved, as well as the extent to which treatments may increase CVD indirectly by increasing cardiovascular risk factors is also important. Systematic collection of data relating treatment details to late effects is needed, and great care is needed to obtain valid and generalisable results. Better knowledge of these cardiac effects will contribute to both primary and secondary prevention of late complications where exposure to cardiotoxic treatment is unavoidable. Also surrogate markers would help to identify patients at increased risk of cardiotoxicity. Evidence-based screening guidelines for CVD following cancer are also needed. Finally, risk prediction models should be developed to guide primary treatment choice and appropriate follow up after cancer treatment.

© 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier Limited. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Improvement in treatment modalities, including radiotherapy and systemic therapies, has led to better prognosis for patients with malignancies [1–3]. Unfortunately, they may also induce late effects including an increased risk of cardiovascular disease (CVD) in long-term survivors [3,4]. In the general population CVDs are major causes of morbidity [5] and
Radiation-related heart disease includes a variety of cardiac diseases typically present 10–15 years later [4,7]. Radiation-related ischaemic heart disease (IHD) is generally observed shortly after exposure. Other radiation-related heart pathologies, such as coronary artery disease, myocardial dysfunction, pericarditis and valvular heart disease [6–8]. Electrical conduction abnormalities have also been reported but data are less consistent. Radiation-related pericarditis usually occurs shortly after exposure. Other radiation-related heart diseases typically present 10–15 years later [4,7]. Radiation-related ischaemic heart disease (IHD) is generally observed at a younger age than IHD in the general population [9–11].

The magnitude of the problem depends on both patient and treatment characteristics (See Tables 1–3). Evidence for a dose-dependent relationship for radiation-related heart disease is accumulating [8,12–14]. Exposure of the heart to even a low radiation dose may lead to an increased risk. A significantly increased risk of death from heart disease (with a linear dose–response relationship) has been observed among the Japanese atomic bomb survivors during the 40 years after exposure to a single dose of <4 Gy [15,16]. Patients treated for peptic ulcer with radiotherapy to the stomach had an increased risk of coronary heart disease which increased with heart dose ($p$ trend = 0.01) [12]. Increased risks of morbidity and mortality from CVD have also been observed after treatment for Hodgkin lymphoma [9,17,18]. Reducing the radiation dose to the heart by shielding a part of the heart (using a subcardinal block) reduced the relative risk for cardiac diseases other than myocardial infarction (MI) [17].

Increased mortality and morbidity from heart disease has also been reported after radiotherapy for breast cancer (BC), especially after some of the radiotherapy techniques that were used in the past [19,20]. Studies on cardiovascular toxicity following radiation for BC frequently compare patients with left-sided and right-sided BC or compare BC patients with the general population (taking into account sex, age and calendar period; see Table 3). Studies comparing patients who have been irradiated with those who have not have also been carried out but, unless they are part of a trial in which patients have been allocated to radiotherapy at random, care must be taken when interpreting them, as patients selected for radiotherapy may differ from other patients in terms of their baseline risks.

In a recent publication 963 women who experienced a major coronary event after radiotherapy for BC between 1958 and 2001 in Sweden and Denmark were compared with 1205 control women who were also irradiated for BC but did not have a major coronary event [14]. An increased risk of major coronary events was observed that started within the first 5 years after radiotherapy and continued into the third decade. The major coronary event rate increased linearly with the mean dose to the heart by 7.4% per Gy (95% confidence interval, 2.9–14.5; $p < 0.001$), with no apparent threshold.

Classical risk factors for coronary artery disease also influence the risk of radiation-related CVDs. Higher risks of developing CVDs following exposure of the heart to radiation have been observed in patients with classical risk factors for CVDs [21]. For example in a large study in 10-year survivors of BC, smoking and radiotherapy together were associated with an even more than additive effect on risk of MI [22].

### Table 1 – Excess risks of cardiac mortality after Hodgkin lymphoma therapy over time.

| Interval (years) | RR | AER | RR | AER | RR | AER | RR | AER |
|-----------------|----|-----|----|-----|----|-----|----|-----|
| 0–5             | 2  | 6.4 | 4.4| 6.3 | 7.6| 6.1 | 1.7| 4.6 |
| 5–10            | 3.6| 20.1| 2.7| 5.3 | 7.0| 10.6| 2.3| 10.9|
| 10–15           | 3.0| 20.5| 2.5| 7.2 | 4.5| 10.7| 1.9| 8.5 | 12.3|
| 15–20           | 5.0| 54.2| 2.8| 13.9| 6.8| 28.7| 4.1| 28.9| 12.3|
| >20             | 5.6| 70.6| 4.5| 41.1| 8.3| 53.9| 3.1| 22.2| 25 |

Adapted from “Long-term complications of lymphoma and its treatment” Ng et al. [85].

Between brackets: year of publication.

BNLI, British National Lymphoma Investigation; CCSS, Childhood Cancer Survival Study; RR, relative risk; AER, absolute excess risk per 10,000 person years.

* Death from myocardial infarction only.
2.1.2. Gaps in knowledge

Although our knowledge concerning radiation-related cardio-toxicity has improved over the last decades there are still many open questions.

Effects of specific doses to the whole heart and to specific cardiac substructures have only been assessed in a few studies [13,14,23]. With the use of more modern radiotherapy-techniques, such as intensity modulated radiotherapy, knowledge about the effects of radiotherapy dose and volume on critical structures of the heart is increasingly important [24].

Furthermore, data on the separate and combined effects of modern radiotherapy and cardiotoxic chemo(immuno)therapy on cardiac disease risk have only been addressed in a small number of studies generally with limited follow-up [9,11,25,26].

Potential interactions between treatment and lifestyle factors (e.g. smoking, hypertension, hypercholesterolemia, premature menopause) need further study especially since improved knowledge may lead to intervention possibilities.

Early detection of (sub)clinical cardiac damage may be important but currently there are no specific guidelines for screening on radiation-related cardiac diseases. At present, in order to prevent such diseases, screening can be aimed only at early detection and at treatment of general risk factors for CVD.

Furthermore, there are indications of large inter-individual variation of susceptibility to treatment-related toxicity and of some variation of genetic susceptibility for radiation-related CVD [27], but further studies are needed.

Since clinical end-points often do not occur until at least 10–15 years after exposure and intervention before they occur may be useful, adequate imaging screening tools and surrogate markers are needed for treatment-related cardiac diseases.

Better knowledge concerning risk factors and mechanisms underlying radiation-related CVDs will contribute to primary and secondary prevention of long-term treatment complications in cancer survivors where exposure of the heart to radiation is unavoidable.

2.2. Cardiotoxicity related to systemic therapy

2.2.1. Current knowledge

The variety of cardiovascular side-effects from systemic cancer therapies is diverse and includes the induction of cardiac dysfunction, myocardial ischaemia, arrhythmias, thromboembolism, arterial and pulmonary hypertension, peripheral arterial occlusive disease and pleural effusion (Table 4)[28]. Cardiotoxicity following systemic treatment is typically associated with loss of myocardial mass, leading to progressive cardiac remodelling and dysfunction. Patients experiencing cardiotoxicity develop heart failure (HF) months to years after the initial cancer therapy and have a severely impaired cardiovascular prognosis [29]. Anthracyclines are a well known example of cardiotoxicity; the pathophysiological mechanism is complex but involves dose-related myocardial cell death during cancer treatment and possibly an impairment of reparatory and homeostatic mechanisms after the exposure to chemotherapy [30,31]. Signalling inhibitors -such as anti-HER2 compounds and angiogenesis inhibitors- were also found to induce cardiac dysfunction. However, in contrast to anthracyclines these drugs typically lead to cardiac dysfunction during cancer treatment with a high potential of reversibility [32]. Furthermore, recent data suggest that patients exposed to trastuzumab have a low risk of progressive cardiac disease even when followed for years after the initial cancer treatment [33]. While cancer drug associated, irreversible cardiotoxicity has recently been termed Type I cardiotoxicity, the reversible form of cardiac dysfunction was named Type II dysfunction [28]. Other cancer drug related cardiovascular side-effects with long-term implications for patients include BCR/ABL tyrosine kinase inhibitor-induced pulmonary hypertension and peripheral arterial occlusive disease [32,34]. These effects typically occur years into treatment with these compounds and the course of the disease remains unclear.

2.2.2. Gaps in knowledge

Although the cardiotoxic risk of conventional chemotherapeutics such as anthracyclines has been recognised for more than 35 years there are still considerable gaps in the

---

Table 2 – Excess risks of cardiac morbidity after Hodgkin lymphoma therapy.

|                      | University of Florida | The Netherlands | Princess Margaret Hospital | Harvard |
|----------------------|-----------------------|-----------------|---------------------------|---------|
|                      | Hull et al. [86] (2003)| Aleman et al. [9] (2007) | Myrehaug et al. [26] (2008) | Galper et al. [87] (2011) |
| CABG                 | 1.63                  | –               | –                         | 3.2     |
| PTCA                | –                     | –               | –                         | 1.6     |
| Valve surgery       | 8.42                  | –               | –                         | 9.2     |
| Pacemaker           | –                     | 3.2             | –                         | –       |
| Ml/angina pectoris  | –                     | 4.9             | 61.7                      | –       |
| CHF                 | –                     | –               | 25.6                      | –       |
| Cardiac hospitalisation | –                     | –               | 1.9                       | 35.6    |

CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; MI, myocardial infarction; CHF, Congestive heart failure; RR, relative risk; AER, absolute excess risk.

Adapted from “Long-term complications of lymphoma and its treatment” Ng et al. [85].
Table 3 – Overview of studies on risk of cardiac disease after RT regimens applied during the 1970s and 1980s.

| First author | Study size | Treatment period | Method of comparison | RR: incidence | RR: mortality |
|--------------|------------|-------------------|----------------------|---------------|--------------|
| Rutqvist (1990) | 54,617 | 1970–1985 | /C24 50 % RT L versus R-sided tumours | MI: 1.09 (1.02–1.17) | [88] |
| Rutqvist (1998) | 5680 | 1976–1987 | Postlumpectomy RT (12%) versus no RT | MI: 0.6 (0.4–1.2) | MI: 0.4 (0.2–1.1) | [89] |
| Højris (1999) | 3083 | 1982–1990 | Postmastectomy RT versus no RT | IHD: 0.86 (0.6–1.3) | IHD: 0.84 (0.4–1.8) | [90] |
| Paszat (1999) | 25,570 | 1982–1987 | Postlumpectomy L versus R-sided RT | MI: 2.10 (1.11–3.95) | [91] |
| Vallis (2002) | 2128 | 1982–1988 | Postlumpectomy L versus R-sided RT | MI: no difference | MI: no difference | [92] |
| Darby (2003) | 89,407 | 1970–1996 | /C160 | CVD *: 1.10 (1.03–1.18) | CVD *: 1.5 (1.19–1.87) | [93] |
| Darby (2005) | 115,165 | 1973–1981 | Several | L versus R-sided RT | CVD *: 1.44 (1.26–1.65) | [54] |
| Patt (2005) | 16,270 | 1986–1993 | Several | L versus R-sided RT | IHD: 1.05 (0.94–1.16) | [95] |
| EBCTCG (2005) | 32,800 | 1961–1991 | Several RT versus no RT | CVD: 1.27 (2.9 = 0.0001) | CVD: 2.7 (2.9 = 0.0001) | [96] |
| Harris (2006) | 961 | 1977–1994 | Postlumpectomy L versus R-sided RT | IHD: 2.7 (1.7–4.5) | CVD: no difference | [21] |
| Hooning (2014) | 4414 | 1970–1986 | Several RT versus no RT | MI: 2.77 (1.62–4.75) | MI: 0.87 (0.47–1.59) | [22] |

L, left; R, right; RT, radiotherapy; RR, relative risk; MI, myocardial infarction; CVD, cardiovascular disease; IHD, ischaemic heart disease; EBCTCG, Early Breast Cancer Trialists Collaborative Group.

Adapted from thesis M.J. Hooning titled Adverse effects of treatment in long-term survivors of breast cancer.

* 10-year survivors

IHD mortality among women treated for breast cancer in 1979; for women diagnosed after 1979 mortality from ischemic heart disease declined by 6% for each successive year until 1988 (HR, 0.79; 95% CI: 0.52–1.18).

The metabolic syndrome is a clustering of metabolic disorders that is associated with a twofold increased risk of CVD compared to the general population. Key components of the understanding of the mechanisms, individual risk factors and prevention of this side-effect (See Table 5). The cardiotoxicity problem is increasing since the introduction of anti-cancer signalling inhibitors that have the potential of causing cardiac dysfunction itself or increasing cardiotoxicity of conventional chemotherapeutics. At present, there is no universally accepted definition of cardiotoxicity and many of the more recent clinical trials that investigated potentially ‘cardiotoxic’ cancer drugs did not differentiate between Type I cardiotoxicity and Type II cardiac dysfunction. Furthermore, since the full spectrum of cardiotoxicity frequently does not become apparent until months or even years after the initial cancer treatment, long-term follow-up of patients exposed to potentially cardiotoxic cancer drugs is needed and early surrogate markers predicting long-term cardiovascular prognosis are wanted. These predictive markers need to be universally applicable and detect early myocardial loss by, for example, measuring high-sensitivity cardiac biomarkers. However, some of the early work with cardiac biomarkers for the prediction of cardiotoxicity has been challenging because the dynamics of biomarker release after chemotherapy was unknown and long-term data confirming the predictive value are missing. It has become clear that the decrease in left ventricular ejection fraction measured either by echocardiography or nuclear scans is not very sensitive in predicting which patient eventually develops cardiotoxicity. Newer imaging techniques such as myocardial strain and strain rate Doppler echocardiography may be more accurate and sensitive to detect early changes of cardiotoxicity. However, these methods may have technical limitations particularly in BC patients after left-sided surgery. Numerous preventive strategies to mitigate cardiotoxicity particularly of anthracyclines have been investigated. They included alterations of the chemical structure, liposomal encapsulation or co-medications to reduce iron chelation. Although some of these strategies appeared successful in reducing cardiotoxicity, questions of impaired efficacy and possible induction of second tumours arose. Global guidelines to treat cardiac dysfunction recommend the early use of renin-angiotensin inhibitors and beta blockers. Although these drugs have been tested to attenuate anthracycline-associated cardiotoxicity in single centre studies, convincing evidence from large randomised multicentre trials are still missing. Finally, although several risk factors for anthracycline-associated cardiotoxicity have been identified, individual risk assessment in patients based on genomics and proteomics is still missing. The recent preclinical discovery that topoisomerase-IIb may mediate anthracycline-associated cardiotoxicity opens exciting new options: the opportunity to develop topoisomerase-IIbalpha specific anthracyclines that are likely less cardiotoxic and also the potential to predict patient’s individual risk for anthracycline-associated cardiotoxicity based on their individual topoisomerase-IIb expression.

2.3. Metabolic syndrome

2.3.1. Current knowledge

The metabolic syndrome is a clustering of metabolic disorders that is associated with a twofold increased risk of CVD compared to the general population. Key components of the
syndrome are decreased insulin sensitivity, hypertension, overweight and an adverse lipid profile. Unfortunately, different classification systems use different criteria to define the metabolic syndrome, creating heterogeneity in reported prevalence between geographical areas and between study populations [41]. Development of the metabolic syndrome may contribute to increased CVD risk in prostate cancer patients using androgen deprivation therapy (ADT), in survivors of testicular cancer (TC) and of childhood malignancies [42–45]. Following standard cisplatin-based chemotherapy, TC survivors have an increased prevalence of the metabolic syndrome compared with the general male population [46]. The metabolic syndrome develops early (3–5 years) after treatment and is associated with decreased serum total testosterone concentration [47]. Childhood cancer survivors of haematological malignancies, mainly acute lymphoblastic leukaemia, and brain tumours have an increased risk of the metabolic syndrome after cranial, abdominal or total body irradiation [44,48]. Development of the metabolic syndrome in these radiotherapy-treated patients is associated with growth hormone deficiency and hypogonadism. Prostate cancer patients may develop an increase in fat mass, a decrease in lean body mass, an adverse lipid profile, and impaired insulin sensitivity early (within 3–6 months) after start of androgen deprivation therapy ADT [49]. These changes differ from the features of the classically defined metabolic syndrome, since ADT induces accumulation of subcutaneous rather than visceral fat, and an increase rather than a decrease in high-density lipoprotein cholesterol. Finally, components of the metabolic syndrome, including weight gain and adverse changes in lipid levels, have been reported in BC survivors [50]. These changes are associated with hormonal therapy and with development of early menopause due to oophorectomy or chemotherapy.

Because of its relatively high prevalence and because of the effects of the metabolic syndrome in cancer survivors, it should be addressed in future care plans. Interventional studies have shown that individuals who make favourable changes in their lifestyle after cancer diagnosis feel better, experience less fatigue and may possibly even decrease risk of cancer recurrence [51].

2.3.2. Gaps in knowledge
Insight into the aetiology of the metabolic syndrome after cancer treatment might help to identify and treat cancer survivors with an increased CVD risk. Early surrogate markers to predict long-term cardiovascular prognosis Early pharmacological intervention to mitigate cardiotoxicity Individualised patient risk assessment

Table 4 – Cardiovascular side-effects of selected systemic cancer therapeutics.

| Cardiovascular effect                  | Cancer therapy        | Long-term effect | Mechanism                      |
|---------------------------------------|-----------------------|------------------|--------------------------------|
| Cardiotoxicity Type I irreversible    | Anthracyclines        | Yes              | Loss of myocardium             |
|                                       | Cyclophosphamide      | Rare             | Myocarditis                    |
|                                       | Cisplatin             | Rare             | Unknown                        |
| Cardiac dysfunction Type II reversible| Anti-HER2 Therapeutics| Unlikely, except when combined with anthracyclines | Mitochondrial dysfunction |
| Myocardial ischaemia                  | Anti-VEGF Therapeutics| Rare             | Coronary vasospasm             |
| Arterial hypertension                 | Arsenic trioxide      | No               | HERG K+ blockage               |
| Pulmonary hypertension                | Cisplatin             | Rare             | Endothelial damage             |
| Peripheral arterial occlusive disease | Anti-VEGF Therapeutics| Unknown          | Multiple mechanisms            |
| Pleural effusion                      | Selected TKIs         | Unknown          | Unknown                        |

Abbreviations: HER2, human epidermal growth factor receptor 2; TKI, tyrosine kinase inhibitors; VEGF, vascular endothelial growth factor, HERG K+, human ether-a-go-go-related gene K+.

Table 5 – Gaps in knowledge concerning cardiotoxicity related to systemic therapy.

Lack of universally accepted definitions of cardiotoxicity and cardiac dysfunction Differentiation between irreversible and reversible cardiac dysfunction Long-term follow-up data (10–20 years) needed Early surrogate markers to predict long-term cardiovascular prognosis Early pharmacological intervention to mitigate cardiotoxicity Individualised patient risk assessment
hormone deficiency and hypogonadism. However, hormonal replacement therapy to counteract adverse metabolic changes can be undesirable from the oncological perspective, as in prostate cancer patients on ADT. Where it is possible, intervention trials to establish the size of any effect of hormonal replacement therapy and its clinical relevance in cancer patients are needed.

Although the metabolic syndrome is associated with an increased CVD risk, other factors, like smoking, genetic predisposition, and co-morbidity also contribute to actual CVD risk. Models incorporating all these factors are needed to better define patients with high and low CVD risk during follow-up.

Current models estimating ten-year CVD risk, like the Framingham risk score, are likely to underestimate the CVD risk, since treatment-related CVD risk certainly continues beyond ten years in cancer survivors. Therefore, life-time instead of ten-year risk predictions for CVD are required for cancer survivor populations. These predictions could identify high risk groups who would benefit from screening and also aid in making treatment decisions.

Finally, the prevalence of the metabolic syndrome in survivors treated with both systemic therapy and radiotherapy is still unknown, but should be assessed during follow-up.

3. Future research

3.1. Learning from the past

There is inevitably uncertainty regarding the long-term effects of the cancer treatments that are currently in use. In contrast, the long-term effects of treatments that have been used in the past can, in principle, be ascertained. However, the treatment that past patients received is now often considered to be outdated. For example, radiotherapy for Hodgkin lymphoma 15–20 years ago consisted of mantle field irradiation up to 40 Gy, a treatment which has little resemblance to the radiotherapy given today [52]. Likewise, systemic treatment has changed substantially during the past few decades. Data on long-term complications from former treatments are still important for long-term survivors treated many years ago. However, they may lead to an exaggerated fear of treatment modalities that have been available for a long time. For example modern radiotherapy approaches generally lead to lower doses to the heart and a dose response relationship has been shown so, lower risks of CVD are expected [53]. There may also be a tendency to underestimate the risks of newer treatment modalities for which long term follow-up information is not available. Nevertheless, the experience of past patients can be one of the richest sources of information on the likely long-term consequences of treatments that are currently in use.

3.2. Randomised trials

One source of information on the long-term experience of patients, is the information collected during the course of phase III trials in which patients satisfying certain prespecified criteria are randomly allocated between two or more different treatment schedules and their subsequent experience compared. Data from large randomised trials performed in the past are particularly useful since treatments were usually standardised, and direct comparisons between treatments are possible.

In general, randomised clinical cancer trials are set up with a time-frame of 5 or 10 years in mind at most. Information on CVD occurring during the first 5 or 10 years is informative [14], but can be of limited use, because many effects may continue into the second decade after treatment [54] and possibly even beyond [4,55]. Therefore, additional follow-up is valuable where it can be obtained. The challenge is to obtain systematic long-term data on patients, since systematic long-term follow-up of patients is expensive and not widely practiced today. Long-term survivorship clinics using dedicated nursing staff and telephone or internet contact with patients may provide a solution.

However, it is often unnecessary to bring patients into the clinic to follow them for late effects, and in several countries useful information can be ascertained at modest cost by matching the list of patients in the trial against national registers of vital status, cause of death and hospital diagnoses [56]. In countries where this is not possible, or where information is required on end-points that are not covered by pre-existing registers, information on late effects can sometimes be obtained by correspondence with the patients themselves [13].

As well as the advantages listed above, randomised studies tend to have some limitations for studying late effects. Individual trials often have very low power for the assessment of late effects (small numbers of patients and/or incomplete data). This difficulty can be overcome by combining information from more than one trial and, preferably, from all the trials carried out in a predefined category, e.g. trials of a particular drug given for a particular cancer. But even this may provide only limited power, especially for cancers in which survival was only moderate at the time the trial was carried out. Many chemotherapy drugs are, however, used for several different cancers and for these drugs, information on late effects from trials carried out in different cancers can be combined to provide adequate power. To accomplish this, more cooperation between different disease-orientated research groups is needed. The Survivorship Taskforce of the EORTC is promoting this by stimulating collaborative projects which include data collection and analyses across different research groups. In some future research projects detailed information may be collected on possible risk factors and outcomes.

A more problematic aspect of the use of randomised trials for studying late effects is that, as they are not pre-specified trial end-points, they are often not reported in papers presenting trial results unless the findings are in some way remarkable. Consequently, systematic reviews that rely just on published information regarding late effects will tend to be able to present only information from studies with extreme results, with obvious consequences in terms of bias. This limitation can be overcome by carrying out a meta-analysis based on individual patient data, although such an approach is resource intensive as it is usually necessary to contact the original investigators of all the trials in a particular category, and
then collate centrally and check all the data that are forthcoming before it can be analysed.

Another limitation of data arising from randomised trials is that patients with substantial co-morbidities at the time of their cancer diagnosis are much less likely to be entered into randomised trials than patients who are otherwise healthy. This is likely to be the case even when such patients are not explicitly excluded in the trial protocol.

A final limitation applies particularly to studies in which the patients in one arm of the trial have been randomised to receive potentially cardiotoxic chemotherapy and patients in the other arm randomised not to receive it. In such trials it is often the case that the patients in the chemotherapy arm have their cardiac status more thoroughly assessed –both during treatment and during follow up- than do patients in the control arm. This may well introduce considerable bias into comparisons between the two trial arms for end-points other than mortality and in such cases meaningful analyses can only be carried out for cardiac mortality.

3.3. Observational studies

Another approach to obtaining information on the cardiac side-effects of cancer treatments is to obtain data from observational studies rather than randomised trials. Such studies can be informative, especially if they are population-based as, for example, studies based on large population-based cancer registries. Care is needed in their interpretation, however, as patients who are at increased risk of heart disease at the time when decisions on their treatment are made, will tend not to be given potentially cardiotoxic chemotherapy if it can possibly be avoided. Comparisons of subsequent heart disease rates in patients with and without such treatment may, therefore, provide misleading answers [56].

3.4. Achieving relevance for today’s patients

Studies of the long-term cardiac effects of cancer treatments given in the past may not be immediately relevant to today’s patients. One reason for this is that medical practice has changed with time. As mentioned before, modern radiation approach has significantly reduced normal tissue exposure. Also in systemic treatment changes have been implemented, for example, the cardiotoxicity of anthracyclines delivered today may be lower than previously due to changes in the way the drug is administered, e.g. by using continuous infusions rather than a bolus or by using a pegylated formulation. Careful consideration of these issues is therefore needed when interpreting any studies. A further issue is that baseline levels of cardiac mortality have decreased substantially over the last few decades in many countries, and levels of morbidity may have also changed, although such changes are generally less well documented than changes in mortality. This may mean that the absolute risk of late cardiac side-effects in patients treated today may differ from that for past populations of patients. Proportional increases in the incidence and mortality arising from the use of particular drugs are, however, usually reasonably stable across populations with different baseline rates.

The experience of the past can also be used to optimise future treatments as the data generated from patients treated in the past may provide dose–response information which can be used in mathematical models and thereby enable us to predict and compare long-term complications of present day treatment, thus guiding the choice of treatment in individual patients [57].

For newer treatments such as antibodies, small molecules, and highly conformal radiotherapy, observation time is still too short for reliable estimation of long-term complications. Vigilance and a strict safety-monitoring programme, even after approval of the drug, are essential.

Furthermore, we need uniform definitions of toxicity in order to allow proper comparison between studies.

3.5. Regulatory issues

For analysis of long-term complications from specific treatments we often need to be able to obtain data from different registries on particular, identifiable patients. Hence, ethical issues must be considered and approvals obtained. In some countries this may be more difficult than in others since there is a large variation in regulations concerning these issues.

Informed consent from all relevant patients may be virtually impossible to obtain retrospectively, since a proportion of patients will have died or their present address may not be known. Moreover, there may be ethical dilemmas when contacting patients treated many years ago who now consider themselves to be healthy. In most countries, permission to omit informed consent is possible in this situation. Another approach could be to incorporate upfront permission from patients entered into clinical trials on future outcomes.

3.6. Early detection of cardiac damage

Information on the possible value of measuring early subclinical damage using biomarkers and/or (functional) imaging following cardiotoxic chemotherapy [58–61] and radiation exposure of the heart [62] is still scarce.

3.6.1. Imaging

Cardiac imaging techniques such as 2D echocardiography or MUGA show clinically detectable left-ventricular dysfunction but earlier subclinical injury cannot be detected with these imaging modalities. Cardiac magnetic resonance imaging (MRI) may offer some possibilities in screening since it enables tissue characterisation and may lead to detection of diffuse interstitial fibrosis and changes in regional myocardial function. MRI also has disadvantages such as need for contrast, and its high cost and low availability. Newer imaging techniques, such as contrast and 3D echocardiography are also under investigation. These imaging modalities are expensive and should not be unnecessarily repeated. Therefore, screening guidelines need to be developed and optimal and cost-effective screening schedules evaluated.

3.6.2. Biomarkers

There are several cardiac biomarkers, such as troponin I (TnI), troponin T (TnT), B-type natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP) and myeloperoxidase (MPO). There may
be a role for these biomarkers during follow-up to enable early detection of cardiac toxicity and possibly also during cancer therapy [63,64]. Circulating cardiac troponin (cTn, which can be TnI or TnT) is a sensitive and specific biomarker for detection of myocardial injury. Although most commonly used to detect myonecrosis in the setting of ischaemia, cTns are also elevated with other acute and chronic disease processes, including HF [65]. An increase in TnI level in patients undergoing chemotherapy may prove to be a useful means of detecting cardiotoxicity long before a reduction in left ventricular ejection fraction (LVEF) occurs and could allow for the selection of high-risk patients who could benefit from preventive treatment, such as treatment with angiotensin-converting enzyme (ACE) inhibitors and beta-blocking agents. In patients treated with trastuzumab, an increase in TnI level could help identifying those patients at risk for cardiotoxicity and unlikely to recover [66]. So far however, treatment is not adapted based on troponin levels.

Serum biomarkers may also be useful in helping diagnose asymptomatic left ventricular dysfunction or HF. Serum biomarkers such as brain natriuretic peptide (BNP) and N-terminal fragment (NT-proBNP) are most commonly used. However, there are limitations to BNP or NT-proBNP measurements, since other diseases may also cause abnormal BNP levels and serum levels also depend on other factors such as age. In a study analysing eight different biomarkers before start of treatment and every three months up to 15 months in patients treated with doxorubicin and trastuzumab, the risk of cardiotoxicity was especially related to an increase in TnI and MPO. The combination of both markers offered additive information about the risk of cardiotoxicity, but independent validation of these findings is necessary before application to clinical practice is possible [37]. Another study evaluating 200 patients with anthracycline-induced cardiomyopathy indicated that the percentage of responders to modern HF treatment decreased progressively as the time from the end of chemotherapy to the start of HF treatment increased [39].

Some biomarkers can also give quantitative information: the absolute value of these markers shortly after the administration of chemotherapy may indicate the degree of future left ventricular dysfunction.

At present there is no clear biomarker-set for CVD risk prediction during or after cancer treatment. Research is on-going regarding the predictive value and the ideal timing of biomarker measurements. Ideally, future research would validate a predictive set of tools to adapt treatment with respect to toxicity risk. Both biomarkers and imaging need further exploration in on-going trials. Early imaging, estimated CVD risk and the ability to associate toxicity with molecular profiling may lead to new recommendations for monitoring cancer patients during and after chemotherapy.

4. Future guidelines

Although the increased risk of cardiac diseases following cancer therapy is well recognised, measures for primary and secondary prevention are still being developed.

Nowadays, cardiac monitoring is done during systemic treatment by serial measurements of left ventricular ejection fraction (LVEF). A decrease in LVEF reflects myocardial injury and the first sign of cardiac failure. Often during chemotherapy this cardiac dysfunction is reversible, and the LVEF decrease is only present at the moment of stress. By introduction of medication or rest, permanent dose reduction or cessation of chemotherapy treatment is not always necessary. What these moments of severe heart stress induce and the impact on cardiovascular risk during the rest of life are not well documented.

Recently, some evidence supports the use of other echocardiographic indices and biomarkers for the earlier detection of cardiac injury before a decrease in LVEF is noticed [67–71]. New imaging tools and markers are sought for earlier detection of serious cardiovascular morbidity partly to enable preventive measures, but also to spare low risk patients from unnecessary monitoring [72,73].

Currently there are no indications that the management of cancer treatment related cardiac diseases should differ from that due to other causes. In patients with (subclinical) HF treatment generally focuses on correcting underlying physiological abnormalities such as increased afterload and decreased contractility, and frequently includes treatment with angiotensin-converting enzyme (ACE) inhibitors and/or beta-blockers [74]. Several guidelines developed for treating patients with asymptomatic left ventricular dysfunction or HF (not specifically after cancer treatment) include e.g. beta-blockers, ACE-inhibitors and diuretics [75].

At this moment, in Europe formal guidelines exist only following antibody treatment (e.g. echocardiograms every three months) [76]. More data on incidence and reversibility, but moreover earlier indicators of cardiac damage, might in the future enable the necessary level of surveillance to be individualised.

Although little is formalised on cardiac surveillance following cancer treatment, it is clear that hypertension, shortness of breath or chronic fatigue need to be taken very seriously in cancer survivors. The risk of late cancer treatment related cardiotoxicity is often forgotten or underestimated, especially in women. Guidelines and educational sessions for general practitioners and other caregivers are needed to explain late cardiac risks and to better anticipate on late effects after cancer treatment [77,78].

Lifestyle factors such as smoking, obesity and lack of exercise and familial predisposition are important risk factors in CVD. Only a few studies have addressed whether factors such as these may modify the risk of treatment-related CVD [51]. Our knowledge of modifying effects of lifestyle and genetic predisposition on treatment-associated cardiovascular risk is only beginning to evolve. International collaborative studies are needed, including large numbers of survivors for whom not only treatment data but also detailed high-quality data on medical history, lifestyle, environmental, and occupational factors are available. The sequence of exposure to treatment and other risk factors deserves investigation, particularly for designing interventions where the treatments interact with modifiable risk factors. International pooling of data already available and data from new studies is essential to obtain sufficient power for interaction analyses allowing discrimination between additive, multiplicative and more than multiplicative effects of treatment and other cancer risk factors. Late effects
research should combine different outcomes like cardiovascular disease, second malignancies, early menopause, infertility etc., to obtain more detailed information on host (genetic sensitivity, lifestyle, age etc.) and treatment (dose, type, timing, interactions etc.) factors. Also the quality of life and psycho-socio-economic impact should be taken into account, having possibly a direct (stress) or in-direct (access to care) influence on morbidity and mortality of various late effects.

Lifestyle interventions, exercise promotion and special care plans are proposed in cancer survivors. Whether all patients will benefit from these measures is uncertain. A risk based strategy is needed and long-term follow-up is essential [51,79–81].

5. Conclusion

Extensive knowledge has already been gained from the past concerning cancer treatment related cardiotoxicity, but there is much more that can be done, although medical practice continues to evolve and so the resulting data need to be interpreted with care. Better knowledge is needed of the late effects of modern systemic treatments and of radiotherapy on critical structures of the heart and of possible interactions between treatment modalities. This knowledge will contribute to a longer life expectancy and better quality of life for cancer survivors, with less treatment-related morbidity from other diseases. Finally, prediction models taking into account the full spectrum of late effects are needed to guide primary treatment choice and appropriate follow up after cancer treatment.

Conflict of interest statement

Maja V. Maraldo were reported by: Berthe M.P. Aleman, Elizabeth C. Moser, Conny Vrieling, Sarah C. Darby.

Thomas M. Suter: Participation in a company sponsored speaker's bureau: Roche, Robopharm, Novartis. Lena Specht: Receipt of grants/research supports: Merck Serono – Receipt of honoraria or consultation fees: Takeda, Boehringer Ingelheim, Fresenius biotech – Participation in a company sponsored speaker's bureau: Takeda.

Reference

[1] Borchmann P, Eichenerauer DA, Engel A. State of the art in the treatment of Hodgkin lymphoma. Nat Rev Clin Oncol 2012;9(8):450–9.

[2] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366(9503):2087–106.

[3] Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707–16.

[4] Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematol Am Soc Hematol Educ Prog 2011;2011:323–9.

[5] de Haas EC, Oosting SF, Lefrandt JD, Wolfpenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol 2010;11(2):193–203.

[6] Schultz-Hector S, Trott KR. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007;67(1):10–8.

[7] Darby SC, Cutter DJ, Boerma M, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys 2010;76(3):656–65.

[8] Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S77–85.

[9] Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109(5):1878–86.

[10] Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117(6):1806–16.

[11] Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99(3):206–14.

[12] Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys 2005;61(3):842–50.

[13] Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.

[14] Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368(11):987–98.

[15] Shimizu Y, Kodama K, Nishi N, et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950–2003. BMJ 2010;340:b5349.

[16] Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors. Report 13: solid cancer and noncancer disease mortality: 1950–1997. Radiat Res 2003;160(4):381–407.

[17] Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270(16):1949–55.

[18] Heidenreich PA, Schnittger I, Strauss HW, et al. Cause-specific mortality after childhood cancer. J Clin Oncol 2010;28(8):1308–15.

[19] Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012.
[25] Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 2012;4:CD006243.

[26] Myrehaug S, Pintillie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49(8):1486–93.

[27] Hilbers FS, Boeckel NB, van den Broek AJ, et al. Genetic variants in TGFB1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol 2012;102(1):115–21.

[28] Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J 2013;34(15):1102–11.

[29] Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracyclines for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010;10:337.

[30] Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011;13(1):1–10.

[31] Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol 1984;2(12):112–7.

[32] de Azambuja AE, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 2009;4(22):77–88.

[33] de Azambuja E, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years median follow-up in the HERA trial (BIG 1-01). JCO 2014 [in press].

[34] Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012;125(17):2128–37.

[35] Harbeck N, Ewer MS, De Laurentiis M, Suter TM, Ewer SM. Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy. Ann Oncol 2011;22(6):1250–8.

[36] Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin i in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13(5):710–5.

[37] Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with Doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63(8):809–16.

[38] Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 2006;7(2):141–6.

[39] Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55(3):213–20.

[40] Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012;18(11):1639–42.

[41] Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640–5.

[42] Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100(19):1368–79.

[43] Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24(27):4448–56.

[44] Nottage KA, Ness KK, Li C, Sriwastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia – from the St. Jude Lifetime Cohort. Br J Haematol 2014.

[45] van den Belt-Dusebout AW, Nuver J, de WR, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3):467–75.

[46] de Haas EC, Altena R, Boezen HM, et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013;24(3):749–55.

[47] Nuver J, Smit AJ, Wolfenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005;23(16):3718–25.

[48] van WM, Negers SJ, van der Leij AJ, Pieters R, van den Heuvel-Eibrink MM. The metabolic syndrome in adult survivors of childhood cancer, a review. J Pediatr Hematol Oncol 2010;32(3):171–9.

[49] Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. J Pediatr Hematol Oncol 2012;35(5):504–9.

[50] Redig AJ, Munshi HC. Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med 2010;123(1). pp. 87.e1–5.

[51] Ligibel J. Lifestyle factors in cancer survivorship. J Clin Oncol 2012;30(30):3697–704.

[52] Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). JCO 2014 [in press].

[53] Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 2012;23(8):2113–8.

[54] Darby SC, McGale P, Taylor CW, Pezo R. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol 2005;6(8):557–65.

[55] Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97(18):1354–65.

[56] McGale P, Darby SC. Commentary: a dose–response relationship for radiation-induced heart disease—current issues and future prospects. Int J Epidemiol 2008;37(3):518–23.

[57] Brodin NP, Maraldo MV, Aznar MC, et al. Interactive decision-support tool for risk-based radiation therapy plan comparison for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;88(2):433–45.

[58] Daugaard G, Lassen U, Bie P, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7(1):87–93.

[59] Aggarwal S, Pettersen MD, Hambhani K, Gurczynski J, Thomas R, L’Ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatr Blood Cancer 2007;49(6):812–6.

[60] Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: a systematic review. Eur J Cancer 2007;43(13):1599–66.

[61] Krawczuk-Rybak M, Dakowicz L, Hryniewicz A, Maksymiuk A, Zelazowska-Rutkowska B, Wysocka J. Cardiac function in long-term survivors of modern treatment for Hodgkin lymphoma. J Paediatr Child Health 2011;47(7):455–9.
[62] D’Enrico MP, Grimaldi L, Petruzelli MF, et al. N-terminal Pro-B-Type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys 2011.

[63] Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 2010;53(2):121–9.

[64] Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30(10):1042–9.

[65] Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J 2011;162(1):64–73.

[66] Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28(25):3910–6.

[67] Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91(5):710–7.

[68] Slamon DJ, Leyland-Jones B, Shak S, et al. Use of trastuzumab in conjunction with chemotherapy versus chemotherapy alone as initial treatment for women with metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783–92.

[69] Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity: course, associations with long-term echocardiographic outcomes. J Clin Oncol 2012;30(10):1042–9.

[70] Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development—considerations for monitoring and management of potential cardiotoxicity: an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration. Am Heart J 2011;162(1):64–73.

[71] Hooning MJ, Aleman BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol 2003;21(18):3431–9.

[72] Ng AK, Lacsace A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011;29(14):1885–92.

[73] Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354(9188):1425–30.

[74] Paszat LF, Mackillop WJ, Groome PA, Schulze K, Holowaty E. Mortality from myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998;40(2):359–63.

[75] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[76] Hoppe RT, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[77] Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011;117(2):412–8.

[78] Rutsivist LE, Johansson H. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[79] Forseyte LP, Parry C, Alfano CM, et al. Use of survivorship care plans in the United States: associations with survivorship care. J Natl Cancer Inst 2013;105(20):1579–87.

[80] Stricker CT, Jacobs LA, Risendal B, et al. Survivorship care planning after the institute of medicine recommendations: how are we faring? J Cancer Surviv 2011;5(4):358–70.

[81] Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet 1999;354(9188):1425–30.

[82] Paszat LF, Mackillop WJ, Groome PA, Schulze K, Holowaty E. Mortality from myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998;40(2):359–63.

[83] Hoppe RT, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[84] Rutsivist LE, Liedberg A, Hammar N, Dalberg K. Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998;40(2):359–63.

[85] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[86] Vallis KA, Pintilie M, Chong N, et al. Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. J Clin Oncol 2002;20(4):1036–42.

[87] Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 2003;326(7383):256–7.

[88] Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2002;94(7):470–8.

[89] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[90] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[91] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[92] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[93] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[94] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[95] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.

[96] Hjorris I, Overgaard M, Christensen JG, Overgaard J. Mortality by laterality of the primary tumour among 55,000 breast cancer patients from the Swedish Cancer Registry. Br J Cancer 1990;61(6):866–8.